Recurrent Neural Networks Can Boost Upstream Processes
Recurrent neural networks (RNNs) could optimize biopharmaceutical processes and even identify potential deviations during process development, according to new research.
Related Articles
Alzheimer’s Mice Have Memory and Brain Function “Rescued” by Cancer Drug
Researchers hope to investigate IDO1 inhibitors in human trials for Alzheimer’s disease in the near future.
Tumors Have a Taste for Fructose, If It’s Transformed by the Liver
Dietary fructose promotes tumor growth in animal models of melanoma, breast cancer, and cervical cancer.
StockWatch: Wall Street’s Leaders and Laggards of 2024
GEN presents data compiled by Morningstar’s Morningstar Direct asset management platform for StockWatch of the top five performing biotech stocks of 2024, and the five…
Tumors Have a Taste for Fructose, If It’s Transformed by the Liver
Dietary fructose promotes tumor growth in animal models of melanoma, breast cancer, and cervical cancer.
SPARDA: A Programmable Nucleic Acid Targeting Technology Like CRISPR
SPARDA and other systems that encode diverse effectors have the potential to offer a novel programmable tool for the field of biotechnology.
Top 10 Contract Development and Manufacturing Organizations 2024
Most leading CDMOs are reporting revenue growth, but according to the CEO of one of these companies, near-term challenges include declining drug discovery activity.
Top 10 U.S. Biopharma Clusters 2024
As much as the world has changed over the past 45 years, its leading regions for biotech activity worldwide are the same now as they…
Organoids Stand Out as Stand Ins in Drug Development
By capturing the genotypic and phenotypic heterogeneity of real tissues, organoids faithfully model human diseases and therapeutic responses.
Top 10 Biopharma Takeover Targets of 2024
Amid expectations for a rise in M&A activity, market watchers are keeping their eyes on biopharma companies that are ripe for the taking.
Top 25 Biotech Companies of 2024
Combined market cap falls 2% year over year, with 16 of the largest public companies losing value and just 5 outperforming the S&P 500.